MA47438A - Structure secondaire de polynucléotide - Google Patents
Structure secondaire de polynucléotideInfo
- Publication number
- MA47438A MA47438A MA047438A MA47438A MA47438A MA 47438 A MA47438 A MA 47438A MA 047438 A MA047438 A MA 047438A MA 47438 A MA47438 A MA 47438A MA 47438 A MA47438 A MA 47438A
- Authority
- MA
- Morocco
- Prior art keywords
- polynucleotide structure
- secondary polynucleotide
- polynucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762453482P | 2017-02-01 | 2017-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47438A true MA47438A (fr) | 2019-12-11 |
Family
ID=63041198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047438A MA47438A (fr) | 2017-02-01 | 2018-02-01 | Structure secondaire de polynucléotide |
Country Status (4)
Country | Link |
---|---|
US (2) | US20200032274A1 (fr) |
EP (1) | EP3577221A4 (fr) |
MA (1) | MA47438A (fr) |
WO (1) | WO2018144778A1 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
LT3981437T (lt) | 2014-04-23 | 2025-01-10 | Modernatx, Inc. | Nuleorūgšties vakcinos |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP4218805A1 (fr) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Vaccins contre les maladies infectieuses |
WO2017020026A1 (fr) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Arn épitopes peptidiques concatémériques |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
ES2922760T3 (es) | 2015-10-22 | 2022-09-20 | Modernatx Inc | Vacunas de virus respiratorios |
PE20181529A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacunas de acido nucleico para el virus varicela-zoster (vzv) |
JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
US20180289792A1 (en) | 2015-10-22 | 2018-10-11 | ModernaTX. Inc. | Sexually transmitted disease vaccines |
JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
WO2017201342A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
SG11201810256XA (en) | 2016-05-18 | 2018-12-28 | Modernatx Inc | Polynucleotides encoding relaxin |
EP3512944B1 (fr) | 2016-09-14 | 2022-07-06 | ModernaTX, Inc. | Compositions d'arn de haute pureté et procédés pour leur préparation |
EP3528821A4 (fr) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
WO2018111967A1 (fr) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Purification par affinité d'arn |
EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
EP3595676A4 (fr) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
EP4397757A3 (fr) | 2017-08-18 | 2024-10-23 | ModernaTX, Inc. | Variants d'arn polymérase |
US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
EP3681514A4 (fr) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Vaccins à arn contre le virus zika |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
WO2020172239A1 (fr) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
EP3938379A4 (fr) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Vaccins à base d'arn contre le vih |
JP2021185136A (ja) | 2020-04-22 | 2021-12-09 | ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルスワクチン |
EP4179112A4 (fr) | 2020-07-13 | 2024-11-20 | The Board of Trustees of the Leland Stanford Junior University | Systèmes et procédés d'évaluation de la stabilité de l'arn |
WO2022015514A1 (fr) * | 2020-07-13 | 2022-01-20 | The Board Of Trustees Of The Leland Stanford Junior University | Systèmes et procédés pour améliorer la stabilité et la traduction de l'arn et leurs utilisations |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11492611B2 (en) | 2020-08-31 | 2022-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for producing RNA constructs with increased translation and stability |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
WO2023201161A1 (fr) * | 2022-04-15 | 2023-10-19 | Thermo Finnigan Llc | Procédé de surveillance quantitative de l'efficacité de coiffage d'arnm |
WO2023235820A1 (fr) * | 2022-06-03 | 2023-12-07 | Eclipse Bioinnovations, Inc. | Procédés d'obtention d'une structure secondaire d'arn d'arn encapsulé dans une npl |
WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
WO2024104914A1 (fr) | 2022-11-14 | 2024-05-23 | BioNTech SE | Dosage d'efficacité de coiffage d'arn |
WO2024156788A1 (fr) * | 2023-01-27 | 2024-08-02 | Eleven Therapeutics Ltd | Molécules polynucléotidiques artificielles pour une stabilité et une traduction améliorées |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1857122E (pt) | 2001-06-05 | 2011-03-07 | Curevac Gmbh | Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral |
US8768630B2 (en) * | 2010-02-19 | 2014-07-01 | The Regents Of The University Of Michigan | miRNA target prediction |
AU2011264879B2 (en) * | 2010-06-11 | 2015-11-12 | Syngenta Participations Ag | Compositions and methods for protein production |
BR112014007852B1 (pt) * | 2011-10-03 | 2021-11-03 | Moderna Therapeutics, Inc | Polinucleotídeo isolado modificado e composição farmacêutica |
WO2014093924A1 (fr) * | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique modifiées et leurs utilisations |
WO2014144767A1 (fr) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Purification d'arnm par échange d'ions |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014144039A1 (fr) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Caractérisation de molécules d'arnm |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
EP2971033B8 (fr) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Procédés de fabrication pour la production de transcrits d'arn |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
PL3146924T3 (pl) | 2015-09-24 | 2023-03-20 | Medinice S.A. | Krioaplikator do mało-inwazyjnej ablacji kardiochirurgicznej |
-
2018
- 2018-02-01 MA MA047438A patent/MA47438A/fr unknown
- 2018-02-01 US US16/483,012 patent/US20200032274A1/en not_active Abandoned
- 2018-02-01 WO PCT/US2018/016514 patent/WO2018144778A1/fr unknown
- 2018-02-01 EP EP18748592.5A patent/EP3577221A4/fr active Pending
-
2023
- 2023-01-04 US US18/093,119 patent/US20230250439A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018144778A1 (fr) | 2018-08-09 |
EP3577221A4 (fr) | 2020-12-23 |
EP3577221A1 (fr) | 2019-12-11 |
US20200032274A1 (en) | 2020-01-30 |
US20230250439A1 (en) | 2023-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47438A (fr) | Structure secondaire de polynucléotide | |
GB2552554B (en) | Resource arrangement | |
BR112017013444A2 (pt) | aperfeiçoamento de procedimento de rach de lte | |
ZA202001147B (en) | Construction component | |
EP3434358A4 (fr) | Mélangeur de liquéfaction | |
EP3331272A4 (fr) | Station de base | |
EP3518359A4 (fr) | Appareillage de commutation | |
EP3440768A4 (fr) | Convertisseur de secteur | |
EP3516530A4 (fr) | Commutateur de sélection | |
FR3023009B1 (fr) | Radar secondaire | |
FR3032494B1 (fr) | Aube de soufflante | |
GB2549996B (en) | Structures | |
HK1247236A1 (zh) | 效能分析 | |
EP3566155A4 (fr) | Expériences partagées | |
FI11882U1 (fi) | Sähkökytkin | |
EP3518358A4 (fr) | Appareillage de commutation | |
PL3420148T3 (pl) | Rynna | |
EP3340807A4 (fr) | Extraits de stévia | |
EP3364058A4 (fr) | Structure de raccord | |
BR112018000296A2 (pt) | ensaios de potência de influenza | |
EP3387316A4 (fr) | Retenue de soufflet | |
GB201704620D0 (en) | Combinations | |
EP3354886A4 (fr) | Engin de construction | |
EP3552449A4 (fr) | Configuration de trajet secondaire | |
GB201810256D0 (en) | Polynucleotide |